Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of Vistusertib (AZD2014) monotherapy in TSC1/2-deficient or TSC1/2-mutant solid tumors refractory to standard chemotherapy
KCT0003961Phase 2Withdrawn
- Sponsor
- Ministry of Health & Welfare
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vistusertib in Nonhematologic neoplasms, sponsored by Ministry of Health & Welfare. Planned start May 2019; status: withdrawn.
02
Drugs
vistusertib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on KCT0003961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003961.